# Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment

Source: https://onco.cc/trials/nct05170438/  
OnCo record `nct05170438` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of gemcitabine, paclitaxel and lenvatinib in gallbladder cancer and other biliary tract cancers, run by National Health Research Institutes, Taiwan, active and no longer recruiting.

## Summary

Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment is a phase 2 interventional study registered as NCT05170438 by National Health Research Institutes, Taiwan, with a registry enrolment figure of 51 participants, started 2022-07-01 and due to reach its primary completion in 2028-06. Interventions recorded: Lenvatinib Pill,Paclitaxel. Conditions listed: Advanced Biliary Tract Cancer. Gallbladder cancer is named in the registry entry: "* 2.Histologically confirmed biliary tract cancer which is locally advanced, recurrent or metastatic disease. The disease entities include intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, distal bile duct c". Sites: Taiwan. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Also known as: LenPac
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT05170438
- Phase: 2
- Setting: Phase II Trial of Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment
- Sponsor: National Health Research Institutes, Taiwan
- Enrolled: 51

## Sources

- ClinicalTrials.gov NCT05170438: https://clinicaltrials.gov/study/NCT05170438

## Connected records

- cancers: [Ampullary cancer (ampulla of Vater)](https://onco.cc/cancers/ampullary/), [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct05170438.json